Trevi starts Phase 3 OCEAN-1 and Phase 2b LAKE trials for Haduvio
Trevi Therapeutics reported second-quarter 2026 results, with cash and securities of $318.9 million and a cash runway extended into 2030.
SEC filing
Latest
2 stories
Thursday, August 6
Thursday, July 23
Serina names Trevi executive Farrell Simon to board, days after amending CEO's pay pact
The Huntsville biotech disclosed a July 19 amended CEO employment agreement before announcing a July 22 board appointment tied to its Parkinson's program SER-252.
SEC filing (2)